MedTrace Logo

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

NCT04729595 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2022-12-06

No results posted yet for this study

Summary

An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.

Conditions

  • Covid19

Interventions

DRUG

Tempol

Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.

OTHER

Placebo

Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.

Sponsors & Collaborators

  • Adamis Pharmaceuticals Corporation

    lead INDUSTRY

Principal Investigators

  • Ronald B Moss, MD · Adamis Pharmaceutical Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-21
Completion
2022-09-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729595 on ClinicalTrials.gov